Quarterly report pursuant to Section 13 or 15(d)

CollabRx Acquisition (Details)

v2.4.0.6
CollabRx Acquisition (Details) (USD $)
 0 Months Ended 9 Months Ended
Jul. 12, 2012
Dec. 31, 2012
Business Acquisition [Line Items]    
Business acquisition effective date Jul. 12, 2012 Jul. 12, 2012
Acquisition agreement date   Jun. 29, 2012
Percentage of interests acquired (in hundredths) 100.00%  
Number of shares issuable to acquire business (in shares)   236,433
Shares issued specified as percentage of total shares outstanding (in hundredths)   14.00%
Interest rate on promissory note (in hundredths) 0.28% 0.28%
RSUs and options granted as "inducement grants" to newly hired management (in shares)   368,417
Vesting period of equity awards   4 years
Noncompetition period   3 years
Stockholders Agreement Period of transfer restrictions and voting provisions   2 years
Assets acquired [Abstract]    
Cash   $ 476,000
AP and Accrueds   (333,000)
Deferred Tax Liability   (664,000)
Goodwill   603,000
Total Acquired Assets, net   1,732,000
Purchase Price summary [Abstract]    
Common Stock Consideration   932,000
Promissory Note Assumed   500,000
Loan/Note Payable Assumed   300,000
Total Purchase Price   1,732,000
Number of clinical and scientific advisors   50
"Big data" opportunity value   300,000,000,000
Tax benefit recognized   52,000
Developed Technology [Member]
    
Assets acquired [Abstract]    
Intangible assets   720,000
Customer Relationships [Member]
    
Assets acquired [Abstract]    
Intangible assets   433,000
Trade Name [Member]
    
Assets acquired [Abstract]    
Intangible assets   346,000
Non Compete Agreements [Member]
    
Assets acquired [Abstract]    
Intangible assets   $ 151,000
Restricted Stock Units (RSUs) [Member]
    
Business Acquisition [Line Items]    
Aggregate RSUs forfeited (in shares)   215,475